Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 8/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.59 |
| ▸ | MIF | P14174 | 5/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.50 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | PCLAF | Q15004 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24881714 | 1.00 | HDAC1 (0.63) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL29908948 | 1.00 | HDAC1 (0.63) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL24882089 | 0.94 | HDAC1 (0.66) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL29908942 | 0.91 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL24881882 | 0.91 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL29908958 | 0.91 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL24881467 | 0.91 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL24880997 | 0.91 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL24881470 | 0.89 | HDAC1 (0.66) | HDAC1HDAC3HDAC2NCOR2CRBN | |
| SCHEMBL24881054 | 0.89 | HDAC1 (0.62) | HDAC1HDAC3HDAC2NCOR2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569563-B2 | Selective HDAC6 degraders and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230011665-A1 | SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-4054607-A1 | SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011665-A1 | SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 4/4885HDAC2 11/4885 |
| US-12569563-B2 | Selective HDAC6 degraders and methods of use thereof | HDAC6, HDAC1, HDAC11 | HDAC1 2/4885HDAC3 4/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.